Fast three‐dimensional image generation for healthy brain aging using diffeomorphic registration

Predicting brain aging can help in the early detection and prognosis of neurodegenerative diseases. Longitudinal cohorts of healthy subjects scanned through magnetic resonance imaging (MRI) have been essential to understand the structural brain changes due to aging. However, these cohorts suffer fro...

Full description

Saved in:
Bibliographic Details
Published inHuman brain mapping Vol. 44; no. 4; pp. 1289 - 1308
Main Authors Fu, Jingru, Tzortzakakis, Antonios, Barroso, José, Westman, Eric, Ferreira, Daniel, Moreno, Rodrigo
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.03.2023
Subjects
Online AccessGet full text
ISSN1065-9471
1097-0193
1097-0193
DOI10.1002/hbm.26165

Cover

Loading…
More Information
Summary:Predicting brain aging can help in the early detection and prognosis of neurodegenerative diseases. Longitudinal cohorts of healthy subjects scanned through magnetic resonance imaging (MRI) have been essential to understand the structural brain changes due to aging. However, these cohorts suffer from missing data due to logistic issues in the recruitment of subjects. This paper proposes a methodology for filling up missing data in longitudinal cohorts with anatomically plausible images that capture the subject‐specific aging process. The proposed methodology is developed within the framework of diffeomorphic registration. First, two novel modules are introduced within Synthmorph, a fast, state‐of‐the‐art deep learning‐based diffeomorphic registration method, to simulate the aging process between the first and last available MRI scan for each subject in three‐dimensional (3D). The use of image registration also makes the generated images plausible by construction. Second, we used six image similarity measurements to rearrange the generated images to the specific age range. Finally, we estimated the age of every generated image by using the assumption of linear brain decay in healthy subjects. The methodology was evaluated on 2662 T1‐weighted MRI scans from 796 healthy participants from 3 different longitudinal cohorts: Alzheimer's Disease Neuroimaging Initiative, Open Access Series of Imaging Studies‐3, and Group of Neuropsychological Studies of the Canary Islands (GENIC). In total, we generated 7548 images to simulate the access of a scan per subject every 6 months in these cohorts. We evaluated the quality of the synthetic images using six quantitative measurements and a qualitative assessment by an experienced neuroradiologist with state‐of‐the‐art results. The assumption of linear brain decay was accurate in these cohorts (R2 ∈ [.924, .940]). The experimental results show that the proposed methodology can produce anatomically plausible aging predictions that can be used to enhance longitudinal datasets. Compared to deep learning‐based generative methods, diffeomorphic registration is more likely to preserve the anatomy of the different structures of the brain, which makes it more appropriate for its use in clinical applications. The proposed methodology is able to efficiently simulate anatomically plausible 3D MRI scans of brain aging of healthy subjects from two images scanned at two different time points. In this work, we proposed a methodology with the aim of simulating subject‐specific aging in brain magnetic resonance imaging (MRI) given two three‐dimensional images acquired at different time points. Deep learning‐based diffeomorphic registration was used as a backbone to generate deformation fields at different integration points. Similarity measurements were used for controlling the age estimation of the generated images by using a linear assumption.
Bibliography:Funding information
As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at
Digital Futures, Grant/Award Number: project dBrain; VINNOVA, Grant/Award Number: 2108; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health, Grant/Award Number: U01 AG024904; DOD ADNI, Grant/Award Number: W81XWH‐12‐2‐0012; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EUROIMMUN Medizinische Labordiagnostika AG; F. Hoffmann‐La Roche Ltd; Genentech, Inc.; Fujirebio US; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research; China Scholarship Council; Center for Innovative Medicine (CIMED); Stockholm County Council and Karolinska Institutet; Hjärnfonden; Alzheimerfonden; Demensfonden; Neurofonden; Stiftelsen För Gamla Tjänarinnor; Fundación Canaria Dr Manuel Morales; Fundación Cajacanarias; Estrategia de Especialización Inteligente de Canarias RIS3 from Consejería de Economía; Industria, Comercio y Conocimiento del Gobierno de Canarias; Programa Operativo FEDER Canarias 2014–2020, Grant/Award Number: ProID2020010063; Barncancerfonden, Grant/Award Number: MT2019‐0019
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
https://adni.loni.usc.edu/
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (https://adni.loni.usc.edu/). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Funding information Digital Futures, Grant/Award Number: project dBrain; VINNOVA, Grant/Award Number: 2108; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health, Grant/Award Number: U01 AG024904; DOD ADNI, Grant/Award Number: W81XWH‐12‐2‐0012; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EUROIMMUN Medizinische Labordiagnostika AG; F. Hoffmann‐La Roche Ltd; Genentech, Inc.; Fujirebio US; GE Healthcare; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research; China Scholarship Council; Center for Innovative Medicine (CIMED); Stockholm County Council and Karolinska Institutet; Hjärnfonden; Alzheimerfonden; Demensfonden; Neurofonden; Stiftelsen För Gamla Tjänarinnor; Fundación Canaria Dr Manuel Morales; Fundación Cajacanarias; Estrategia de Especialización Inteligente de Canarias RIS3 from Consejería de Economía; Industria, Comercio y Conocimiento del Gobierno de Canarias; Programa Operativo FEDER Canarias 2014–2020, Grant/Award Number: ProID2020010063; Barncancerfonden, Grant/Award Number: MT2019‐0019
ISSN:1065-9471
1097-0193
1097-0193
DOI:10.1002/hbm.26165